Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
•
Oncology
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib?
What treatment combinations be used to maximize results?
Related Questions
After achieving clinical response to bexarotene for cutaneous lymphoma (e.g., MF stage Ib or FMF), do you wean to the lowest dose for sustained remission, and if so, when?
How would you treat a basal cell carcinoma on the temporal skin and zygomatic area s/p excision with PNI and significant flaps for closure?
Have you used itraconazole as a primary or adjunct therapy for individuals with numerous BCCs?
How would you manage a scalp squamous cell carcinoma s/p Mohs with high risk features who underwent placental grafting to expedite the healing process?
How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
How effective is the use of genomic testing methods, such as tape strip tests, for assessing suspicious pigmented lesions in clinical practice?
Would you favor radiation or immune modulating treatment like imiquimod to treat an uncomplicated basal cell carcinoma on the nose in an elderly patient for whom you'd like to avoid surgery?
In what situations would you recommend adjuvant radiation therapy for patients with locally advanced and/or recurrent basal cell carcinoma that receive vismodegib followed by surgery?
What approach, or dosing interval, do you find is most effective reducing side effects of Hedgehog Inhibitors (i.e., vismodegib) for patients with numerous BCC?